Listed biopharmaceutical company GroPep Limited (ASX: GRO) todayannounced the release of a novel Assay kit to be used in the detectionof a range of diseases, including cancer.
The Assay kit ? which detects human IGFBP-3 – is highly specific andsensitive and can detect minute samples of the molecule in humanserum or plasma.
The kit is expected to generate considerable interest in the global research market and has potential to add significantly to the Company’s Biomedical Research Products sales.
This is the third ELISA (Enzyme-linked Immunosorbent Assay) Kit resulting from the strategic alliance between GroPep and UK-based kit manufacturer Immunodiagnostic Systems Limited (IDS).
Playing to their respective strengths, GroPep develops, produces andsupplies antibodies and antigens to IDS, who use these products to develop and manufacture ELISA kits for the research and diagnostic markets.
What is IGFBP-3?
IGFBP-3 is the major Insulin-like growth factor binding protein in bloodcontrolling the concentration of free Insulin-like growth factor I (IGF-I)available for cell growth.
What is an ELISA Kit?
An ELISA Kit contains all the components required for the assay. One antibody binds hIGFBP-3 from serum and another specific antibody with an enzyme detection system bound to it, allows development of colour proportional to the amount of hIGFBP-3 in the sample. This colour is read off against a standard curve of known quantities of IGFBP-3.